Patents by Inventor Pritiranjan Bhandari

Pritiranjan Bhandari has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical compositions of tenecteplase
    Patent number: 9943575
    Abstract: Pharmaceutical compositions of tenecteplase that are safe and effective in the treatment of acute ischemic stroke compared with the known compositions are disclosed. The compositions of the invention are invented based on a series of testing trials on the different amounts of the TNK and isolating specific amount that is optimally suitable in terms of desired effects of TNK in the treatment of acute ischemic stroke.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: April 17, 2018
    Assignee: Gennova Biopharmaceuticals Limited
    Inventors: Maheshwari Kumar Mishra, Pritiranjan Bhandari, Sanjay Singh
  • PHARMACEUTICAL COMPOSITIONS OF TENECTEPLASE
    Publication number: 20160310580
    Abstract: Pharmaceutical compositions of tenecteplase that are safe and effective in the treatment of acute ischemic stroke compared with the known compositions are disclosed. The compositions of the invention are invented based on a series of testing trials on the different amounts of the TNK and isolating specific amount that is optimally suitable in terms of desired effects of TNK in the treatment of acute ischemic stroke.
    Type: Application
    Filed: April 22, 2016
    Publication date: October 27, 2016
    Inventors: Maheshwari Kumar MISHRA, Pritiranjan BHANDARI, Sanjay SINGH
  • PHARMACEUTICAL COMPOSITIONS OF TENECTEPLASE
    Publication number: 20130323227
    Abstract: Pharmaceutical compositions of tenecteplase that are safe and effective in the treatment of acute ischemic stroke compared with the known compositions are disclosed. The compositions of the invention are invented based on a series of testing trials on the different amounts of the TNK and isolating specific amount that is optimally suitable in terms of desired effects of TNK in the treatment of acute ischemic stroke.
    Type: Application
    Filed: December 16, 2011
    Publication date: December 5, 2013
    Applicant: Gennova Biopharmaceuticals Limited
    Inventors: Maheshwari Kumar Mishra, Sanjay Singh, Pritiranjan Bhandari